Environmental DNA and Hydroacoustic Surveys for Monitoring the Spread of the Invasive European Catfish ( Linnaeus, 1758) in the Guadalquivir River Basin, Spain.

The European catfish ( Linnaeus, 1758) was introduced into the Ebro Basin in Spain in 1974 for recreational fishing. Since then, the species has spread throughout the country's river basins, reaching the Iznájar Reservoir (Guadalquivir River Basin) in 2011. This area is of great ecological and economic relevance, especially as it includes the Doñana National Park, one of the most important nature reserves in Europe.

Bilirubin Removal With Therapeutic Plasma Exchange Or Molecular Adsorbent Recirculating System (MARS®) As Treatment For Cholemic Nephropathy In Patients With Cirrhosis and ACLF: A case series.

Introduction: Cholemic nephropathy is an overlooked cause of acute kidney injury (AKI) in patients with advanced cirrhosis and high bilirubin plasma levels (usually above 20mg/dl), due to bilirubin and bile acid deposition in the kidneys. Those deposits have been hypothesized to cause tubular injury. It has no standardized diagnostic criteria or therapeutic strategies.

Effectiveness of oral platelet lysate gel to treat oral mucosal manifestations associated with chronic graft versus host disease.

Background: Chronic graft-vs-host disease (cGvHD) is a severe immune-mediated complication that affects patients following allogeneic hematopoietic stem cell transplantation (allo-HSCT). Oral manifestations of cGvHD, such as ulcers and mucosal inflammation, significantly impair quality of life and often require long-term treatment. Existing therapies provide limited relief, prompting the exploration of new approaches, including the use of autologous platelet lysate (PL) gel for its regenerative properties.

Optimized GVHD Prevention in HLA-Mismatched Unrelated Allogeneic HCT Using a PTCY-Based Approach.

Although post-transplant cyclophosphamide (PTCY)-based prophylaxis has become a widely adopted strategy for preventing graft-versus-host disease (GVHD) in 9 out of 10 HLA-mismatched unrelated donors (MMUDs), allogeneic hematopoietic cell transplants (allo-HCTs), data on the safety and efficacy of PTCY in this setting remain limited. This single-center study investigates the outcomes of 94 adults with hematological malignancies undergoing MMUD allo-HCT with PTCY and tacrolimus (Tac) (PTCY-Tac) between 2014 and 2023. The median age was 53 years, and 60.